Cellectis Capital Surpluse from 2010 to 2024

CLLS Stock  USD 2.13  0.01  0.47%   
Cellectis Capital Surpluse yearly trend continues to be comparatively stable with very little volatility. Capital Surpluse will likely drop to about 731 M in 2024. From the period from 2010 to 2024, Cellectis Capital Surpluse quarterly data regression had r-value of  0.88 and coefficient of variation of  28.50. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
970 M
Current Value
731 M
Quarterly Volatility
188 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cellectis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.4 M, Interest Expense of 6.7 M or Selling General Administrative of 30.4 M, as well as many indicators such as Price To Sales Ratio of 223, Dividend Yield of 0.0 or PTB Ratio of 3.61. Cellectis financial statements analysis is a perfect complement when working with Cellectis Valuation or Volatility modules.
  
Check out the analysis of Cellectis Correlation against competitors.

Latest Cellectis' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Cellectis SA over the last few years. It is Cellectis' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectis' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Cellectis Capital Surpluse Regression Statistics

Arithmetic Mean659,730,456
Geometric Mean634,803,456
Coefficient Of Variation28.50
Mean Deviation171,373,094
Median614,037,000
Standard Deviation188,040,422
Sample Variance35359.2T
Range501.6M
R-Value0.88
Mean Square Error8596.4T
R-Squared0.77
Significance0.000015
Slope36,997,848
Total Sum of Squares495028.8T

Cellectis Capital Surpluse History

2024731 M
2023970 M
2019843.5 M
2018828.5 M
2017614 M
2016568.2 M

About Cellectis Financial Statements

Cellectis shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Cellectis investors may analyze each financial statement separately, they are all interrelated. The changes in Cellectis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cellectis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse970 M731 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cellectis Stock Analysis

When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.